This study focuses on developing a disease-modifying therapy (DMT) for synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy caused by the propagation and aggregation of α-synuclein (α-syn). Specifically, we aim to target α-syn seeds through various approaches, such as apheresis therapy, specific antibody therapy, nucleic acid therapy, suppression of inter-neuronal propagation using deep brain stimulation, neuromodulation with drugs, and promoting the degradation of aggregates. By combining these strategies, we seek to establish effective DMTs for synucleinopathies. Additionally, we plan to generate pathogenic α-syn mouse models to conduct reverse translational research.